美国老年成年人接种COVID-19 mRNA疫苗后潜在不良事件的比较风险
该回顾性队列研究利用链接的药房与Medicare理赔数据库,纳入2020年12月11日至2021年7月11日期间首次接种mRNA-1273或BNT162b2的6388196名66岁及以上社区居住、按服务收费的老年人,随访28天。调整协变量后,mRNA-1273组肺栓塞风险略低于BNT162b2组(RR 0.96,95%CI 0.93-1.00;RD 9/10万人,95%CI 1-16),诊断COVID-19风险也更低(RR 0.86,95%CI 0.83-0.87),但衰弱者中该获益减弱(RR 0.94,95%CI 0.89-0.99)。两组所有结局风险均低。作者认为,mRNA-1273可能因对COVID-19保护更强而伴随略低的不良事件风险,未来研究应区分疫苗安全性与有效性差异并考虑衰弱的作用。
要点
- 在6388196名≥66岁美国老年人中,mRNA-1273较BNT162b2的肺栓塞风险略低(RR 0.96,95%CI 0.93-1.00;RD 9/10万人,95%CI 1-16)。
- mRNA-1273组诊断COVID-19风险低于BNT162b2组(RR 0.86,95%CI 0.83-0.87),但衰弱者中获益减弱(RR 0.94,95%CI 0.89-0.99)。
- 亚组分析显示,非衰弱个体中mRNA-1273组血小板减少性紫癜风险低11.0%。
- 两组12种潜在不良事件风险均低;38.1%为衰弱前期,6.0%为衰弱。
- 作者认为,mRNA-1273可能因对COVID-19保护更强而伴随略低的不良事件风险,未来研究应区分疫苗安全性与有效性差异。
适用人群与场景
- 社区居住、按服务收费的Medicare受益人,年龄≥66岁,首次接种mRNA-1273或BNT162b2 COVID-19疫苗。
- 数据来源为链接的社区药房与Medicare理赔数据库,覆盖超过50%的美国Medicare人群。
诊断标准与关键阈值
- 衰弱程度采用基于理赔的衰弱指数评估,分为非衰弱、衰弱前期和衰弱三类。
研究设计与关键结果
- 研究类型为回顾性队列研究,纳入6388196名首次接种mRNA-1273或BNT162b2的≥66岁美国老年人,平均(SD)年龄76.3(7.5)岁,59.4%为女性,86.5%为白人,38.1%为衰弱前期,6.0%为衰弱。
- 主要结局为12种潜在不良事件(如肺栓塞、血小板减少性紫癜、心肌炎),两组所有结局风险均低。
- 调整模型显示,mRNA-1273组肺栓塞风险低于BNT162b2组(RR 0.96,95%CI 0.93-1.00;RD 9/10万人,95%CI 1-16)。
- 亚组分析显示,非衰弱个体中mRNA-1273组血小板减少性紫癜风险低11.0%。
- 次要结局诊断COVID-19风险在mRNA-1273组低于BNT162b2组(RR 0.86,95%CI 0.83-0.87),衰弱者中该获益减弱(RR 0.94,95%CI 0.89-0.99)。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,mRNA-1273可能因对COVID-19保护更强而伴随略低的不良事件风险;未来研究应正式区分疫苗安全性与有效性差异,并在评估COVID-19疫苗性能时考虑衰弱的作用。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Head-to-head safety comparisons of the mRNA vaccines for SARS-CoV-2 are needed for decision making; however, current evidence generalizes poorly to older adults, lacks sufficient adjustment, and inadequately captures events shortly after vaccination. Additionally, no studies to date have explored potential variation in comparative vaccine safety across subgroups with frailty or an increased risk of adverse events, information that would be useful for tailoring clinical decisions.
OBJECTIVE: To compare the risk of adverse events between mRNA vaccines for COVID-19 (mRNA-1273 and BNT162b2) overall, by frailty level, and by prior history of the adverse events of interest.
DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study was conducted between December 11, 2020, and July 11, 2021, with 28 days of follow-up following the week of vaccination. A novel linked database of community pharmacy and Medicare claims data was used, representing more than 50% of the US Medicare population. Community-dwelling, fee-for-service beneficiaries aged 66 years or older who received mRNA-1273 vs BNT162b2 as their first COVID-19 vaccine were identified. Data analysis began on October 18, 2022.
EXPOSURE: Dose 1 of mRNA-1273 vs BNT162b2 vaccine.
MAIN OUTCOMES AND MEASURES: Twelve potential adverse events (eg, pulmonary embolism, thrombocytopenia purpura, and myocarditis) were assessed individually. Frailty was measured using a claims-based frailty index, with beneficiaries being categorized as nonfrail, prefrail, and frail. The risk of diagnosed COVID-19 was assessed as a secondary outcome. Generalized linear models estimated covariate-adjusted risk ratios (RRs) and risk differences (RDs) with 95% CIs.
RESULTS: This study included 6 388 196 eligible individuals who received the mRNA-1273 or BNT162b2 vaccine. Their mean (SD) age was 76.3 (7.5) years, 59.4% were women, and 86.5% were White. A total of 38.1% of individuals were categorized as prefrail and 6.0% as frail. The risk of all outcomes was low in both vaccine groups. In adjusted models, the mRNA-1273 vaccine was associated with a lower risk of pulmonary embolism (RR, 0.96 [95% CI, 0.93-1.00]; RD, 9 [95% CI, 1-16] events per 100 000 persons) and other adverse events in subgroup analyses (eg, 11.0% lower risk of thrombocytopenia purpura among individuals categorized as nonfrail). The mRNA-1273 vaccine was also associated with a lower risk of diagnosed COVID-19 (RR, 0.86 [95% CI, 0.83-0.87]), a benefit that was attenuated by frailty level (frail: RR, 0.94 [95% CI, 0.89-0.99]).
CONCLUSIONS AND RELEVANCE: In this cohort study of older US adults, the mRNA-1273 vaccine was associated with a slightly lower risk of several adverse events compared with BNT162b2, possibly due to greater protection against COVID-19. Future research should seek to formally disentangle differences in vaccine safety and effectiveness and consider the role of frailty in assessments of COVID-19 vaccine performance.
参考来源
- Harris DA, Hayes KN, Zullo AR, et al. Comparative Risks of Potential Adverse Events Following COVID-19 mRNA Vaccination Among Older US Adults. JAMA Netw Open. 2023. PMID: 37531110. doi:10.1001/jamanetworkopen.2023.26852
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。